Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A strain of Bifidobacterium breve with anti-influenza ability and its application

A technology for Bifidobacterium breve and influenza, applied in the field of microorganisms, can solve problems such as obvious side effects

Active Publication Date: 2020-12-29
无锡食生臻选生物科技有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, it may be possible to start with gut microbes and try to find new drugs or methods for the prevention and treatment of influenza, so as to overcome the shortcomings of existing drugs and treatment methods with obvious side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A strain of Bifidobacterium breve with anti-influenza ability and its application
  • A strain of Bifidobacterium breve with anti-influenza ability and its application
  • A strain of Bifidobacterium breve with anti-influenza ability and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1: Screening and Identification of Bifidobacterium breve CCFM1026 and B1

[0048] 1. Screening

[0049] Take human feces as a sample, store the sample in about 20% glycerol in a -80°C refrigerator, take it out and thaw it, mix the sample evenly, draw 0.5mL of the sample and add it to 4.5mL of 0.9% normal saline containing 0.05% cysteine ​​for gradient Dilution, select 10 -3 、10 -4 、10 -5 The diluted solution of the dilution factor was spread on the MRS plate with 0.05% cysteine, cultured at 37°C for 48 hours, picked typical colonies to streak and purify on the MRS plate, picked a single colony and transferred it to the liquid MRS medium (containing 0.05% cysteine) was enriched and preserved in 30% glycerol to obtain strain CCFM1026 and strain B1.

[0050] 2. Identification

[0051] The genomes of CCFM1026 and B1 were extracted, the 16S rDNA of CCFM1026 and B1 were amplified and sequenced (Shanghai Sangon Bioengineering Co., Ltd.), and the sequences were com...

Embodiment 2

[0052] Embodiment 2: the cultivation of Bifidobacterium breve

[0053] Bifidobacterium breve (Bifidobacterium breve) CCFM1026 was cultivated in MRS medium (containing 0.05% cysteine) at 37° C. for 48 h, then transferred to fresh MRS medium (containing 0.05% cysteine), and Conditioned culture for 30 hours, centrifuge the cells at 6000 g for 15 min, wash the cells with 0.9% normal saline and then centrifuge again at 6000 g for 10 min to obtain the cells, resuspend with 30% sucrose solution, and freeze at -80°C until use.

[0054] Observing the bacteria, its taxonomic characteristics are: the bacteria are short rod-shaped, Gram staining is positive, methylene blue staining is irregular, no spores, flagella and capsules, no movement; the colony characteristics are: round white; Its growth characteristics are as follows: culturing under anaerobic conditions at 37°C for 30 hours can reach a stable period, and utilize glucose for atypical heterolactic fermentation.

Embodiment 3

[0055] Example 3: Effect of Bifidobacterium breve on body weight of influenza mice

[0056] 32 healthy ICR female mice weighing 20-24 g were randomly divided into 4 groups, and the 4 groups were respectively named: blank control group (Control), influenza model group (Model), drug treatment group administered with ribavirin (Treatment). ), Bifidobacterium breve CCFM1026 intervention group (CCFM1026), Bifidobacterium breve B1 intervention group (B1 group), 8 rats in each group.

[0057] 2 weeks before the experiment, the Bifidobacterium breve intervention group (CCFM1026) was administered 10 times a day 9 Bifidobacterium breve bacterial suspension dilution of CFU bacteria amount, Bifidobacterium breve B1 intervention group (B1) intragastric administration of the same amount of Bifidobacterium breve B1 bacterial suspension dilution, and the remaining groups (Control, Model, Treatment) intragastric administration every day 0.2mL physiological saline.

[0058] On the first day o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a bifidobacterium breve with anti-influenza ability and application thereof, belonging to the technical field of microorganisms and the technical field of medicine. The Bifidobacterium breve of the present invention has anti-influenza effect, which is embodied in: (1) significantly improving the weight loss degree of influenza mice; (2) significantly improving the blood index of influenza mice; (3) significantly improving influenza Respiratory tract infection inflammation status of mice; (4) significantly enhance the expression of antiviral protein MxA in the lungs of influenza mice, therefore, Bifidobacterium breve (Bifidobacterium breve) of the present invention is used in the preparation of products for preventing and / or treating influenza , has great application prospects.

Description

technical field [0001] The invention relates to a strain of bifidobacterium breve with anti-influenza ability and application thereof, belonging to the technical field of microbes and the technical field of medicine. Background technique [0002] Influenza is often a pandemic in autumn and winter, mainly caused by influenza virus. Influenza viruses can be divided into three types: influenza A virus, influenza B virus, and influenza C virus. Human influenza is mainly caused by influenza A virus and influenza B virus. Generally, animal influenza viruses do not infect humans, and human influenza viruses do not infect animals, but pigs are an exception. Pigs can be infected with both avian influenza virus and human influenza virus, but they are mainly infected with avian influenza virus. However, once they are infected with avian influenza virus, they can easily infect humans and cause a human influenza pandemic. [0003] For example, the "Spanish flu" that occurred in 1819-19...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20A23L29/00C12R1/01
CPCA61K2035/115A23L29/065A23L33/135A61P31/16C12N1/205C12R2001/01
Inventor 陈卫陆文伟翟齐啸刘馨阳崔树茂赵建新张灏
Owner 无锡食生臻选生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com